Celldex Therapeutics, Inc.
NASDAQ: CLDXHampton, US · Delaware corporation · 1 known investors
Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Founders & leadership
AS
Anthony S. MarucciFounder
AW
Avery W. CatlinExecutive
TM
Timothy M. Shannon, M. D.Named on SEC filing
Board
RV
Richard van den BroekBoard director
HJ
Herbert J. ConradBoard director
KS
Karen ShoosBoard director
LE
Larry EllbergerBoard director
GO
George O. ElstonBoard director
HH
Harry H. Penner, Jr.Board director
Investors · 1
Funding
SEC filings, press & company announcements$409.5M disclosed across 3 rounds · 2014–2026
- $345MraisedApr 2026 · 2 sourcesSource ↗
▶$62.5MraisedNov 2016 · 29 investors · BiotechnologyRule 506(b)
▶$62.5MraisedNov 2016 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Herbert J. ConradDirector
- Anthony S. MarucciExecutive Officer, Director
- Karen ShoosDirector
- Richard van den BroekDirector
- Larry EllbergerDirector
- Avery W. CatlinExecutive Officer
- George O. ElstonDirector
- Harry H. Penner, Jr.Director
- Offering amount
- $62.5M
- Amount sold
- $62.5M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2014 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen ShoosDirector
- George O. ElstonDirector
- Herbert J. ConradDirector
- Avery W. CatlinExecutive Officer
- Harry H. Penner, Jr.Director
- Timothy M. Shannon, M. D.Director
- Anthony S. MarucciExecutive Officer, Director
- Larry EllbergerDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Exelixis42 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Kite Pharma33 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Celldex Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upsidetradingview.com · Aug 2026Frequently asked questions
- What does Celldex Therapeutics, Inc. do?
- Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
- Who founded Celldex Therapeutics, Inc.?
- Celldex Therapeutics, Inc. was founded by Anthony S. Marucci.
- Who are Celldex Therapeutics, Inc.'s investors?
- Celldex Therapeutics, Inc.'s investors include Foresite Capital.
- How much funding has Celldex Therapeutics, Inc. raised?
- Celldex Therapeutics, Inc. has disclosed $409.5M raised across 3 rounds.
- Where is Celldex Therapeutics, Inc. headquartered?
- Celldex Therapeutics, Inc. is headquartered in Hampton, US.